急性白血病靶向药物与生物治疗的感染并发症:欧洲白血病感染会议(ECIL)临床实践指南
ECIL-9于2021年9月16-17日以网络会议形式召开,综述了治疗急性髓系白血病(AML)和急性淋巴细胞白血病(ALL)的新型免疫治疗药物和分子靶向药物相关的感染及发热性中性粒细胞减少风险。专家组基于证据制定了感染并发症预防和管理推荐及药物相互作用警示,并经全体会议讨论达成共识后发布。
要点
- 多数新型靶向药物单药治疗未显著增加感染风险。
- 维奈克拉联合去甲基化药物、吉妥珠单抗联合细胞毒药物或米哚妥林加入常规AML化疗时需谨慎。
- 指南制定了感染并发症预防和管理推荐及药物相互作用警示。
核心结论
- 多数新型药物单药治疗未显著增加感染风险,但维奈克拉联合去甲基化药物、吉妥珠单抗联合细胞毒药物或米哚妥林加入常规AML化疗等联合治疗需谨慎。
研究设计与样本
- 第9届欧洲白血病感染会议(ECIL-9)于2021年9月16-17日以网络会议形式召开,专家组综述了新型免疫治疗药物和分子靶向药物治疗AML和ALL的感染及发热性中性粒细胞减少风险,并制定推荐直至达成共识。
主要发现
- 综述的药物包括抗体类药物(奥加伊妥珠单抗、吉妥珠单抗奥唑米星、flotetuzumab)、异柠檬酸脱氢酶抑制剂(艾伏尼布、恩西地平、olutasidenib)、FLT3激酶抑制剂(吉瑞替尼、米哚妥林、奎扎替尼)、hedgehog抑制剂(格拉吉布)及BCL2抑制剂(维奈克拉),评估了其作用机制、免疫抑制潜力、当前获批情况及临床研究报告的感染并发症和发热性中性粒细胞减少。
关键数值与推荐
- 多数药物单药治疗未显著增加感染风险;维奈克拉联合去甲基化药物、吉妥珠单抗奥唑米星联合细胞毒药物或米哚妥林加入常规AML化疗时需谨慎。
临床怎么用
- 原文未据此给出具体临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The 9th web-based European Conference on Infections in Leukemia (ECIL-9), held September 16-17, 2021, reviewed the risk of infections and febrile neutropenia associated with more recently approved immunotherapeutic agents and molecular targeted drugs for the treatment of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Novel antibody based treatment approaches (inotuzumab ozogamicin, gemtuzumab ozogamicin, flotetuzumab), isocitrate dehydrogenases inhibitors (ivosidenib, enasidenib, olutasidenib), FLT3 kinase inhibitors (gilteritinib, midostaurin, quizartinib), a hedgehog inhibitor (glasdegib) as well as a BCL2 inhibitor (venetoclax) were reviewed with respect to their mode of action, their immunosuppressive potential, their current approval and the infectious complications and febrile neutropenia reported from clinical studies. Evidence-based recommendations for prevention and management of infectious complications and specific alerts regarding the potential for drug-drug interactions were developed and discussed in a plenary session with the panel of experts until consensus was reached. The set of recommendations was posted on the ECIL website for a month for comments from members of EBMT, EORTC, ICHS and ELN before final approval by the panelists. While a majority of these agents are not associated with a significantly increased risk when used as monotherapy, caution is required with combination therapy such as venetoclax plus hypomethylating agents, gemtuzumab ozogamicin plus cytotoxic drugs or midostaurin added to conventional AML chemotherapy.
引用
- Maschmeyer G, Bullinger L, Garcia-Vidal C, et al. Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN). Leukemia. 2022. PMID: 35368047. doi:10.1038/s41375-022-01556-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。